Similar articles

• Optimizing bortezomib treatment in patients with relapsed multiple myeloma.

  Richardson P. Richardson P. Clin Adv Hematol Oncol. 2006 May;4(5):4-5; discussion 8; suppl 13. Clin Adv Hematol Oncol. 2006. PMID: 16832859 No abstract available.
• Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

  Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E. Dimopoulos MA, et al. Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059. Clin Lymphoma Myeloma. 2009. PMID: 19717380
• [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].

  Mitina TA, Golenkov AK, Kataeva EV, Lutskaia TD, Trifonova EV, Klinushkina EF. Mitina TA, et al. Ter Arkh. 2010;82(7):57-61. Ter Arkh. 2010. PMID: 20853611 Clinical Trial. Russian.
• Management of multiple myeloma with bortezomib: experts review the data and debate the issues.

  Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P. Dicato M, et al. Oncology. 2006;70(6):474-82. doi: 10.1159/000099284. Epub 2007 Feb 2. Oncology. 2006. PMID: 17283449 Review.
• Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

  Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG. Badros A, et al. Cancer. 2007 Sep 1;110(5):1042-9. doi: 10.1002/cncr.22921. Cancer. 2007. PMID: 17654660 Review.